逸達生物科技 Foresee Pharmaceuticals Co., Ltd.
  • About Us
    • Company Profile
    • Business Model
    • Board of Directors
    • Management Team
    • Scientific Advisory Board
    • Others
  • R & D
    • Pipeline Overview
    • SIF Pipeline
      • FP-001:Prostate Cancer; Central Precocious Puberty
      • FP-014:Prostate Cancer
      • FP-016:Neurology/Psychiatry
      • FP-004:Opioid Dependence/Pain
      • FP-011:Breast Cancer
      • Other Research Projects
    • NCE Pipeline
      • FP-025:Asthma; Acute Exacerbations of COPD/ILD
      • FP-045: Fanconi Anemia; Cardiovascular, Renal and Metabolism (CVRM); Peripheral artery disease (PAD)
      • FP-020: Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema
      • FP-040: CNS Diseases
  • Media
    • Press Release
    • Media Library
  • Investors
    • Corporate Governance
      • Corporate Charters
      • Board of Directors
      • Others
    • Material Information
    • News & Events
      • Press Releases
      • Events & Presentations
    • Financial Information
      • Financial Results
      • Monthly Revenues
    • Sharholder Information
      • Annual General Meeting
      • Major Shareholders
      • FAQs
      • Investor Contacts
    • Others
  • Career
    • Benefits
    • Join Us
  • Contact Us
  • 繁體中文
  • HOME
  • 繁體中文
  • HOME
Latest News
2022/12/20 Investor Conference : Corporate presentation slides available
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord Healthcare to Head the E.U. Commercialization
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
  • Press Release

  • Pipeline Overview

  • Financial Information

  • Join Us

Foresee Pharmaceuticals Co., Ltd.

Copyright © 2020 Foresee Pharmaceuticals Co., Ltd. All rights reserved.